Conversely, Carmeliet's group confirmed a key role of PlGF in tumour neovascularisation, as PlGF blockage inhibits vessel abnormalisation in certain tumours, thus enhancing VEGF-targeted inhibition (Van de Veire et al, 2010). The gene discussed is VEGFA; the disease is neoplasm.